| Name | Title | Contact Details |
|---|
Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening with open minds • Committed to each other
Attune Pharmaceuticals is a private biotechnology company focused on discovering and developing novel orally-administered small-molecule therapeutics for the treatment of rare diseases.
Oxis International, Inc. has formed and provided initial financing to support the activities of its wholly owned subsidiary, Oxis Biotech, Inc. The parent company, Oxis International is engaged in the research, development and sale of products to counteract oxidative stress and inflammation. Oxis Biotech is focused on the acquisition of cannabis related intellectual properties and commercialization of therapies developed from the intellectual properties to treat certain diseases.
Immune Tolerance Network is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.